ALX Oncology
ALXO
106 hedge funds and large institutions have $510M invested in ALX Oncology in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 10 closing their positions.
295% more call options, than puts
Call options by funds: $1.58M | Put options by funds: $400K
130% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 10
14% more funds holding
Funds holding: 93 → 106 (+13)
0.56% less ownership
Funds ownership: 91.86% → 91.3% (-0.56%)
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
25% less capital invested
Capital invested by funds: $681M → $510M (-$171M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$13.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$9.37M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.54M |
| 4 |
Squarepoint
New York
|
+$1.49M |
| 5 |
Goldman Sachs
New York
|
+$931K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.6M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.74M |
| 3 |
O
OrbiMed
New York
|
-$5.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.36M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.56M |
ALXO Hedge Fund Activity: Q1 2024 in Review
106 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2024, worth a combined $510M — down 25% from $681M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ALXO positions and 10 closed out — a net gain of 13 holders — while 28 added to existing stakes and 31 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $13.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $13.6M sold.
- 106 institutional investors held ALX Oncology (ALXO) as of Q1 2024, up from 93 in Q4 2023.
- Funds reported $510M of ALX Oncology stock for Q1 2024, down 25% quarter-over-quarter.
- 23 funds opened new ALX Oncology positions in Q1 2024 and 10 closed out, a net change of +13 holders.
- The largest ALX Oncology buyer in Q1 2024 was Vestal Point Capital, an estimated $13.4M added.
- The largest ALX Oncology seller in Q1 2024 was Point72 Asset Management, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2024.